Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: Adv Drug Deliv Rev. 2012 Nov 2;65(1):49–59. doi: 10.1016/j.addr.2012.10.014

Figure 1.

Figure 1

A) The design of the combination HPMA copolymer-based macromolecular therapeutics for improving the treatment of prostate cancer, by targeting both bulk cancer cells and prostate cancer stem cells (CSC)s. B) Summary of changes of CD133+ prostate CSCs and whole cell viabilities following in vitro exposure of RC-92a/hTERT prostate cancer cells to HPMA copolymer-cyclopamine conjugate (P-CYP), free cyclopamine (CYP) or docetaxel (DTX). Black columns: CD133 expression level (%); gray columns: cell viability (%). The data are presented as mean±SD of the experiments done in triplicate. *, p < 0.05; **, p < 0.01. Vehicle (DMSO) treated and untreated cells were used as controls. Adapted with from [61].